

Media Release

Synthes Statement Regarding Receipt of Subpoena from Attorney General of New Jersey

West Chester, PA (USA), February 6, 2008

Synthes (SWX: SYST.VX) announced today that Synthes Spine, Inc., a subsidiary of Synthes, Inc., has received an administrative subpoena from the Attorney General of New Jersey.

Under the subpoena, Synthes Spine, Inc., is ordered to deliver certain documents and information concerning its ProDisc[®] line of products. Synthes will cooperate fully in responding to the subpoena.

The document requests set forth in the subpoena suggest, among other things, that the Attorney General of New Jersey is investigating the clinical development, marketing and promotion of the ProDisc line of products, including professional service and consulting agreements.

At this point in the investigation, Synthes does not know when the investigation will conclude.

Synthes: A leading medical device company

Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.

For further information please contact

Gilgian Eisner, Investor Relations, Synthes, Inc.
Phone +41 32 720 47 45, Fax +41 32 720 48 11, e-mail ir.info@synthes.com

<http://www.synthes.com/>

Restrictions subject to US-Securities Law

SYNTHES MANAGEMENT BELIEVES CERTAIN STATEMENTS IN THIS PRESS RELEASE MAY CONSTITUTE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE STATEMENTS INCLUDE BUT ARE NOT LIMITED TO THOSE WITH RESPECT TO THE POTENTIAL FOR SYNTHES TO OFFER NEW PRODUCTS AND MARKET EXISTING ONES, AS WELL AS THE EXPECTED SALES AND SALES GROWTH OF SYNTHES. THESE STATEMENTS ARE MADE ON THE BASIS OF MANAGEMENT'S VIEWS AND ASSUMPTIONS REGARDING FUTURE EVENTS AND BUSINESS PERFORMANCE AS OF THE TIME THE STATEMENTS ARE MADE. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED. SUCH DIFFERENCES MAY RESULT FROM THE ABILITY OF SYNTHES TO SUCCESSFULLY DEVELOP AND INTRODUCE NEW PRODUCTS AND SERVICES AND MARKET EXISTING PRODUCTS AND SERVICES IN A COMPETITIVE MARKETPLACE AND CHANGES IN THE ECONOMIC CONDITIONS THAT MAY AFFECT THE PERFORMANCE OF THE OPERATIONS OF SYNTHES. IN ADDITION, CHANGES IN COMPETITIVE CONDITIONS AND REGULATORY DEVELOPMENTS MAY AFFECT FUTURE BUSINESS PERFORMANCE, AND CHANGING MARKET CONDITIONS MAY AFFECT THE VALUATION OF SYNTHES SECURITIES. IN ADDITION, IT SHOULD BE NOTED THAT PAST FINANCIAL AND OPERATIONAL PERFORMANCE OF THE COMPANY IS NOT NECESSARILY INDICATIVE OF FUTURE FINANCIAL AND OPERATIONAL PERFORMANCE. SYNTHES UNDERTAKES NO OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

THE SECURITIES OF SYNTHES, INC. HAVE BEEN OFFERED AND SOLD OUTSIDE THE UNITED STATES AND HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED ("THE SECURITIES ACT"). SUCH SECURITIES MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED IN REGULATION S OF THE SECURITIES ACT), EXCEPT PURSUANT TO A REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OR UNDER AN APPLICABLE EXEMPTION UNDER THE SECURITIES ACT. HEDGING TRANSACTIONS INVOLVING SUCH SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT. THE SYNTHES SECURITIES ARE DEEMED "RESTRICTED SECURITIES" AS THAT TERM IS DEFINED IN RULE 144 UNDER THE SECURITIES ACT.